Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02140151
Other study ID # ML29258
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date September 17, 2014
Est. completion date July 9, 2020

Study information

Verified date August 2022
Source Southern California Desert Retina Consultants, MC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will determine whether quarterly injections of Ranibizumab may prevent eyes with dry age-related macular degeneration from progressing to wet age-related macular degeneration (AMD).


Description:

This is a multicenter, prospectively randomized, masked and controlled, interventional investigator sponsored phase I/II study of subjects with high-risk nonexudative age-related macular degeneration (AMD) treated with intravitreal ranibizumab quarterly for prophylaxis of conversion to exudative age-related macular degeneration. The objective of this study is to investigate the safety and efficacy of prophylactic anti-vascular endothelial growth factor (VEGF) therapy with ranibizumab to prevent the development of exudative AMD in eyes with high-risk nonexudative AMD. In addition, baseline characteristics of high-risk eyes (fundus features, optical coherence tomography (OCT) parameters and genetic profile) will be evaluated to determine their predictive value in conversion to exudative AMD. The effect of ranibizumab on the atrophic component of AMD will also be monitored.


Recruitment information / eligibility

Status Completed
Enrollment 108
Est. completion date July 9, 2020
Est. primary completion date July 9, 2020
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria: - Adult over 50 years old - Able to sign informed consent and comply with the study protocol for the duration of two years - Nonexudative age-related macular degeneration (AMD) in one eye (study eye) - History of exudative AMD in one eye only (fellow eye) diagnosed within 5 years of study enrollment Exclusion Criteria: - Participation in another simultaneous medical investigation or clinical trial - Patient is pregnant, lactating, or premenopausal and not using adequate contraception - Known serious allergies to ranibizumab, fluorescein dye, drugs for pupillary dilation, topical anesthetic, sterilizing solution (e.g. Betadine solution) - Presence of ocular conditions with increased risk of choroidal neovascularization (CNVM) or pigment epithelial detachment (PED), including presumed ocular histoplasmosis syndrome (POHS), traumatic choroidal rupture, angioid streaks, pathologic myopia (spherical equivalent of = -8 diopters or axial length of = 25 mm), multifocal choroiditis, macular choroidal nevus, polypoidal choroidal vasculopathy (PCV), idiopathic central serous chorioretinopathy (ICSC), etc. - History of vitrectomy in the study eye - History of cataract surgery within 3 months of enrollment - History of yttrium aluminum garnet (YAG) capsulotomy within 1 month of enrollment - History of intraocular or periocular corticosteroid therapy within the past 90 days - History of therapeutic radiation in the region of the study eye. - Presence of media opacity that would preclude adequate examination and/or imaging - Concurrent macular conditions that would affect the study parameters (epiretinal membrane, macular hole, macular edema) or require treatment within the duration of the study - Any progressive ocular condition (uncontrolled glaucoma, diabetic retinopathy, uveitis) that may affect the visual acuity for the duration of the study - Active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye at enrollment - Presence of any advanced systemic condition that may hinder the patients participation and completion of the study - Concurrent use of systemic anti-VEGF therapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ranibizumab 0.5mg


Locations

Country Name City State
United States Elman Retina Baltimore Maryland
United States Northern California Retina Vitreous Associates Mountain View California
United States Southern California Desert Retina Consultants Palm Desert California
United States Black Hills Regional Eye Institute Rapid City South Dakota

Sponsors (1)

Lead Sponsor Collaborator
Southern California Desert Retina Consultants, MC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Development of exudative AMD Development of choroidal neovascularization (conversion) defined by the presence of leakage on fluorescein angiography (FA) and fluid within or below the retina or below the retinal pigment epithelium seen on spectral-domain optical coherence tomography (SD-OCT) 2 years
Secondary Vision change Change in best-corrected visual acuity (BCVA) from baseline at 12 and 24 months 2 years
Secondary Vision loss Proportion of eyes losing < 5, 10, and 15 letters on EDTRS chart at 12 and 24 months 2 years
Secondary Number of injections Number of injections required in eyes that convert from dry to wet AMD during the study period 2 years
Secondary Baseline predictive factors Baseline demographic, genetic and ocular characteristics predictive of development of wet AMD 2 years
Secondary Development of geographic atrophy (GA) Development of geographic atrophy (GA) as detected by fundus photography (FP) and/or fundus autofluorescence (AF). 2 years
Secondary Ocular adverse events Incidence and severity of ocular adverse events, as identified by eye examination and imaging 2 years
Secondary Systemic adverse events Incidence and severity of other adverse events, as identified by physical examination or subject reporting. 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05984927 - NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT05536297 - Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy Phase 3
Recruiting NCT04101604 - Biomarkers of Common Eye Diseases
Completed NCT04005352 - Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON) Phase 3
Withdrawn NCT02873351 - A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration Phase 2
Active, not recruiting NCT02802657 - Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration Phase 4
Not yet recruiting NCT02864472 - Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose Phase 4
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT01445548 - Sirolimus for Advanced Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT02035722 - Intravitreal Injections-related Anxiety Phase 2/Phase 3
Completed NCT01175395 - 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Recruiting NCT01048476 - Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration Phase 1/Phase 2
Active, not recruiting NCT01174407 - Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration N/A
Terminated NCT00712491 - Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT00345176 - Age-Related Eye Disease Study 2 (AREDS2) Phase 3
Completed NCT02555306 - A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration Phase 1/Phase 2
Recruiting NCT04796545 - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration N/A
Completed NCT03166202 - Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
Completed NCT01397409 - Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD) Phase 2
Recruiting NCT06174181 - Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration N/A